以下文章来源于e公司 ，作者证券时报 吴志 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 东星医疗拟收购武汉医佳宝90%股权。 9月26日，东星医疗（301290）公告，拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝"或"标的公司"）90%的股权。此次交易如能 顺利实施，武汉医佳宝将成为东星医疗的控股子公司。 根据公告，此次收购基于公司业务发展战略的需要。 具体来看，东星医疗拟以支付现金的方式，收购武汉医佳宝90%的股权。若本次交易能顺利实施完成，公司将持有武汉医佳宝90%的股权。 目前，此次交易尚处于初步筹划阶段。2025年9月26日，东星医疗已经与武汉医佳宝全体股东签订了《股权收购意向协议》，但最终收购股权比例、交易对方 及交易价格尚需交易各方进一步协商后确定。 东星医疗表示，根据初步研究和测算，本次交易预计构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次交易不会导致上市公司控股 ...

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][7]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [7]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [11]. - A exclusivity period is established from the signing of the agreement until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [12]. Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [14]. - Wuhan Yijiaobao specializes in the research, production, and sales of high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [14][16]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022 [18]. - From 2021 to 2024, the company's net profit after deducting non-recurring gains and losses has decreased from 1.03 billion to approximately 66.46 million [19]. - In the first half of 2025, Dongxing Medical reported a 14.17% year-on-year decline in revenue to 183.29 million, and a 36.47% drop in net profit to 30.29 million [22].

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][10] Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [3][4] - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [9] - A exclusivity period is set from the signing date until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [9] Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [11][13] - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [11][13] Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [15] - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% year-on-year to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [18][19]

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [1][2]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [2]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [7]. - A exclusivity period is established from the signing date until May 31, 2026, during which the sellers cannot negotiate with other parties regarding the equity transfer [7]. Group 2: Strategic Intent - The acquisition is part of Dongxing Medical's strategic need for business development and aims to extend its surgical medical device industry chain while actively expanding into the synthetic biology field [8]. - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [8][10]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [11]. - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [13][14].

基于公司业务发展战略的需要具体来看，东星医疗，90%的股权。若本次交易能顺利实施完成，公司将 持有武汉医佳宝90%的股权目前，此次。东星医疗已经与，但东星医疗表示，东星医疗2025年6月，公 司委托上海交通大学进行重组胶原蛋白的研发，拟拓展合成生物业务板块。武汉医佳宝是一家致力于高 端骨科及生物医学材料研发、生产与销售的高新技术企业。 拟收购武汉医佳宝9月26日，东星医疗（301290）公告，"武汉医佳宝"或"标的公司"）90%的股权 交易 如能顺利实施，武汉医佳宝将成为 的控股子公司。 武汉医佳宝东星医疗表示，此次。 的股权关系较为清晰，其只有两名股东，分别为持股9月26日，东星医疗股价收于27.96元/股，市值约 28亿元。截至今年9月，公司股东约1.04万户。 ...

Group 1 - Dongxing Medical plans to acquire 90% stake in Wuhan Yijiaobao, which is expected to constitute a major asset restructuring. The acquisition aligns with the company's strategic development needs and aims to enhance its competitive strength in the orthopedic and biomedical materials sector [1] - Yonghui Supermarket received a warning letter from Sichuan Securities Regulatory Bureau for failing to timely disclose equity changes after reducing its stake in Hongqi Chain from 11% to 10%. The company will enhance its compliance training and improve information disclosure practices [1] - Xinhua Jin announced that due to non-operational fund occupation by related parties and failure to rectify within one month, its stock will be renamed to ST Xinhua Jin, with a daily price limit of 5%. The outstanding non-operational fund occupation amounts to 406 million yuan [3] Group 2 - Zhongke Lanyun is making forward-looking investments in high-growth areas such as GPU and AI, holding shares in companies like Muxi Integrated Circuit and Moer Thread, with ownership percentages of 0.24% and 0.34% respectively [2] - Yousheng Co. received a project notification from a well-known German automaker for battery tray products, with a total sales amount expected to be approximately 2.3 billion yuan [4] - *ST Songfa's subsidiary signed contracts for the construction of four vessels, with a total value between 400 million to 600 million USD [5]

公告显示，武汉医佳宝是一家致力于高端骨科及生物医学材料研发、生产与销售的高新技术企业。本次 交易是基于公司业务发展战略的需要及从公司长远利益出发做出的慎重决策，符合公司整合行业优质资 源，延伸公司外科医疗器械产业链，积极拓展合成生物领域的发展布局，有利于公司综合实力的提升， 对公司未来业务发展及经营业绩提升将产生积极影响。 北京商报讯（记者 丁宁）9月26日晚间，东星医疗(301290)发布公告称，公司拟以支付现金方式购买武 汉医佳宝生物材料有限公司（以下简称"武汉医佳宝"）90%的股权，预计构成重大资产重组。交易完成 后，武汉医佳宝将成为公司的控股子公司。 ...

Joint Ventures and Investments - Baiyun Airport announced a joint investment with China Duty Free Group to establish a duty-free company with a registered capital of 45 million yuan, where China Duty Free Group holds a 51% stake [3] - Dongxing Medical plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., a high-tech enterprise focused on orthopedic and biomedical materials [4] - Fosun Pharma's subsidiary is planning to transfer 100% of Shanghai Cloning's equity to enhance asset operation efficiency, with a transaction value of up to 1.256 billion yuan [5] Corporate Actions - New Sai Co. announced the resignation of its director and general manager, Chen Jianjiang, due to work adjustments [7] - Hailiang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries [8] - Zhejiang University Network New plans to sell 48.6 million shares of Wanliyang, expecting a transaction amount of 475 million yuan [9] Contracts and Orders - Haitai Development's subsidiary signed a property sale contract worth 440 million yuan, expected to increase the company's profit by approximately 62.86 million yuan in 2025 [12] - Dongjie Intelligent's overseas subsidiary received a procurement order worth approximately 180 million yuan, accounting for 22.3% of the company's audited revenue for 2024 [13] - Zhiguang Electric's subsidiary signed a procurement contract worth 164 million yuan for high-voltage energy storage systems [14] - ST Songfa's subsidiary signed contracts for the construction of four oil tankers, with a total contract value between 400 million to 600 million USD [15] - Huaguang Huaneng signed a sales contract for waste heat boilers worth 160 million yuan for a power plant project in Cambodia [16] Regulatory and Compliance - Jingliang Holdings received an administrative regulatory decision from Hainan Securities Regulatory Bureau for violations related to trade activities, involving an income amount of 299 million yuan [18] Shareholder Actions - Zaiseng Technology's controlling shareholder plans to reduce its stake by up to 3%, amounting to approximately 30.9 million shares [20] - Compton plans to reduce its repurchased shares by up to 1%, totaling approximately 2.5644 million shares [21] Financing Activities - Qibin Group obtained a special financing support of up to 90 million yuan for share repurchase from Industrial and Commercial Bank of China [23] - Xianhe Co. plans to raise up to 3 billion yuan through a private placement for a high-performance paper-based new materials project [25]

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

武汉医佳宝是一家致力于高端骨科及生物医学材料研发、生产与销售的高新技术企业。本次交易是基于 公司业务发展战略的需要及从公司长远利益出发做出的慎重决策，符合公司整合行业优质资源，延伸公 司外科医疗器械产业链，积极拓展合成生物领域的发展布局，有利于公司综合实力的提升，对公司未来 业务发展及经营业绩提升将产生积极影响。 东星医疗（301290）(301290.SZ)发布公告，公司拟以支付现金方式购买武汉医佳宝生物材料有限公司 (简称"武汉医佳宝")90%的股权，本次交易如能顺利实施，武汉医佳宝将成为公司的控股子公司。根据 初步研究和测算，本次交易预计构成《上市公司重大资产重组管理办法》规定的重大资产重组。 ...